Bioneer Rises 18.31% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 18th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.09% compared to the previous day, showing strength, while Bioneer, which is gaining attention as a related stock, surged by 18.31% compared to the previous day. Bioneer is known as a gene technology specialized company.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Bioneer's quant financial score was 2.65 points, ranking 49th in the quant financial ranking within the COVID-19 (diagnosis/treatment/vaccine development, etc.) related theme. This can be interpreted as Bioneer having relatively low investment attractiveness from a financial perspective. On the other hand, United Pharm ranked first in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialized company Thinkpool.

This content was produced with the assistance of AI translation services.